Natural Product (NP) Details
| General Information of the NP (ID: NP7303) | |||||
|---|---|---|---|---|---|
| Name |
Silymarin
|
||||
| Synonyms |
Milk thistle extract; Sabal serrulata extract; 84604-20-6; AN-35849; FT-0656490; A835184; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2H-1-benzopyran-4-one; (2S)-3,5,7-trihydroxy-2-[(2S,3R)-3-(4-hydroxy-3-methoxy-phenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chroman-4-one
Click to Show/Hide
|
||||
| Species Origin | Carduus marianus ... | Click to Show/Hide | |||
| Carduus marianus | |||||
| Disease | Colorectal cancer [ICD-11: 2B91] | Phase 4 | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C25H22O10
|
||||
| PubChem CID | |||||
| Canonical SMILES |
COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4C(C(=O)C5=C(C=C(C=C5O4)O)O)O)CO)O
|
||||
| InChI |
1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3
|
||||
| InChIKey |
SEBFKMXJBCUCAI-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 65666-07-1
|
||||
| Herb ID | |||||
| SymMap ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combined applications of doxorubicin and silymarin caused higher apoptosis and necrosis of cells in 24 h than that of single agent applications. | |||||
| β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Experimental
Result(s) |
Silymarin possess protective effects against cisplatin hepatotoxic action in animal models. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Arachidonate 5-lipoxygenase (5-LOX) | Molecule Info | [4] | |
| BioCyc | Aspirin-triggered lipoxin biosynthesis | Click to Show/Hide | ||
| 2 | Resolvin D biosynthesis | |||
| 3 | Leukotriene biosynthesis | |||
| 4 | Lipoxin biosynthesis | |||
| 5 | Aspirin triggered resolvin D biosynthesis | |||
| 6 | Aspirin triggered resolvin E biosynthesis | |||
| KEGG Pathway | Arachidonic acid metabolism | Click to Show/Hide | ||
| 2 | Metabolic pathways | |||
| 3 | Serotonergic synapse | |||
| 4 | Ovarian steroidogenesis | |||
| 5 | Toxoplasmosis | |||
| NetPath Pathway | IL4 Signaling Pathway | Click to Show/Hide | ||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | Click to Show/Hide | ||
| WikiPathways | Vitamin D Receptor Pathway | Click to Show/Hide | ||
| 2 | Arachidonic acid metabolism | |||
| 3 | Eicosanoid Synthesis | |||
| 4 | Selenium Micronutrient Network | |||
